Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation

被引:151
作者
Bittencourt, H
Rocha, V
Chevret, S
Socié, G
Espérou, H
Devergie, A
Dal Cortivo, L
Marolleau, JP
Garnier, F
Ribaud, P
Gluckman, E
机构
[1] Hop St Louis, Serv Hematol Greffe Moelle, Bone Marrow Transplant Unit, Cell Therapy Lab, F-75475 Paris 10, France
[2] Hop St Louis, Biostat Unit, F-75475 Paris 10, France
关键词
D O I
10.1182/blood.V99.8.2726
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although CD34 cell dose is known to influence outcome of peripheral stem cell - and/or T-cell-depleted transplantation, such data on unmanipulated marrow transplantation are scarce. To study the influence of CD34(+) cell dose on hematopoletic reconstitution and Incidence of infections after bone marrow transplantation, we retrospectively analyzed 212 patients from January 1994 to August 1999 who received a transplant of an unmanipulated graft from an HILA-Identical sibling donor. Median age was 31 years; 176 patients had hematologic malignancies. Acute graft-versus-host disease prophylaxis consisted mainly in cyclosporin associated with methotrexate (n = 174). Median number of bone marrow nucleated cells and CD34+ cells infused were 2.4 x 10(8)/kg and 3.7 x 10(6)/kg, respectively. A CD34+ cell dose of 3 x 106/kg or more significantly influenced neutrophil (hazard ratio [HR] = 1.37, P = .04), monocyte (HR = 1.47, P = .02), lymphocyte (HR = 1.70, P = .003), erythrocyte (HR = 1.77, P = .0002), and platelet (HR = 1.98, P = .00008) recoveries. CD34+ cell dose also influenced the incidence of secondary neutropenia (HR = 0.60, P = .05). Bacterial and viral infections were not Influenced by CD34 cell dose, whereas it influenced the incidence of fungal infections (HR = 0.41, P = .008). Estimated 180-day transplantation-related mortality (TRM) and 5-year survival were 25% and 56%, respectively, and both were highly affected by CD34(+) cell dose (HR = 0.55, P = .006 and HR = 0.54, P = .03, respectively). Five-year survival and 180-day TRM were, respectively, 64% and 19% for patients receiving a CD34(+) cell dose of 3 x 106/kg or more and 40% and 37% for the remainders. In conclusion a CD34(+) cell dose of 3 x 10(6)/kg or more Improved all hematopoietic recoveries, decreased the incidence of fungal Infections and TRM, and Improved overall survival. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:2726 / 2733
页数:8
相关论文
共 44 条
  • [1] Anasetti C, 1999, BLOOD, V94, p561A
  • [2] Bahçeci E, 2000, BRIT J HAEMATOL, V108, P408
  • [3] Barrett AJ, 2000, BLOOD, V95, P3323
  • [4] Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
    Bensinger, WI
    Martin, PJ
    Storer, B
    Clift, R
    Forman, SJ
    Negrin, R
    Kashyap, A
    Flowers, MED
    Lilleby, K
    Chauncey, TR
    Storb, R
    Appelbaum, FR
    Rowley, S
    Heimfeld, S
    Blume, K
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (03) : 175 - 181
  • [5] Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Societe Francaise de Greffe de Moelle
    Blaise, D
    Kuentz, M
    Fortanier, C
    Bourhis, JH
    Milpied, N
    Sutton, L
    Jouet, JP
    Attal, M
    Bordigoni, P
    Cahn, JY
    Boiron, JM
    Schuller, MP
    Moatti, JP
    Michalle, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) : 537 - 546
  • [6] AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    ABRAMS, JH
    BERNARD, GR
    BIONDI, JW
    CALVIN, JE
    DEMLING, R
    FAHEY, PJ
    FISHER, CJ
    FRANKLIN, C
    GORELICK, KJ
    KELLEY, MA
    MAKI, DG
    MARSHALL, JC
    MERRILL, WW
    PRIBBLE, JP
    RACKOW, EC
    RODELL, TC
    SHEAGREN, JN
    SILVER, M
    SPRUNG, CL
    STRAUBE, RC
    TOBIN, MJ
    TRENHOLME, GM
    WAGNER, DP
    WEBB, CD
    WHERRY, JC
    WIEDEMANN, HP
    WORTEL, CH
    [J]. CRITICAL CARE MEDICINE, 1992, 20 (06) : 864 - 874
  • [7] Champlin RE, 2000, BLOOD, V95, P3702
  • [8] A proportional hazards model for the subdistribution of a competing risk
    Fine, JP
    Gray, RJ
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) : 496 - 509
  • [9] Garnier F, 2000, BLOOD, V96, p409A
  • [10] Outcome of cord-blood transplantation from related and unrelated donors
    Gluckman, E
    Rocha, V
    BoyerChammard, A
    Locatelli, F
    Arcese, W
    Pasquini, R
    Ortega, J
    Souillet, G
    Ferreira, E
    Laporte, JP
    Fernandez, M
    Chastang, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) : 373 - 381